These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 6482017)

  • 41. [Clinical investigation for recurrence and progression in Ta grades 1 and 2 bladder cancer].
    Takei K; Kotake T; Masai M; Ito H; Nagao K; Chiba K; Saito K; Hirokawa M
    Hinyokika Kiyo; 1997 Mar; 43(3):185-9. PubMed ID: 9127752
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
    Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
    Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Carcinoma in a bladder diverticulum: presentation and treatment outcome.
    Golijanin D; Yossepowitch O; Beck SD; Sogani P; Dalbagni G
    J Urol; 2003 Nov; 170(5):1761-4. PubMed ID: 14532771
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
    J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Watchful waiting policy in recurrent Ta G1 bladder tumors.
    Gofrit ON; Pode D; Lazar A; Katz R; Shapiro A
    Eur Urol; 2006 Feb; 49(2):303-6; discussion 306-7. PubMed ID: 16413659
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
    Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
    Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.
    Kwak C; Ku JH; Park JY; Lee E; Lee SE; Lee C
    J Urol; 2004 Jan; 171(1):149-52. PubMed ID: 14665864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The risk factors of bladder tumors stage "A". Description of a new parameter (author's transl)].
    Steg A; Allouch G; Deslignières S
    Sem Hop; 1980 Apr 18-25; 56(15-16):738-43. PubMed ID: 6246608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical studies of patients with bladder cancers].
    Nakagawa Y; Matsuda T; Kawamura H; Murota T; Ohara T; Komatsu Y
    Hinyokika Kiyo; 1992 Apr; 38(4):389-94. PubMed ID: 1529810
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Five year follow-up of patients with cancer of the bladder--the Northern Alberta experience.
    Koch M; McPhee MS; Gaedke H; Williams Y
    Clin Invest Med; 1988 Aug; 11(4):253-8. PubMed ID: 3168348
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Urothelial bladder tumors in stage pTa. I.--What is the risk for the patient?].
    Bittard H
    J Urol (Paris); 1990; 96(5):263-5. PubMed ID: 2230190
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Stage Ta/T2 bladder tumors: prognostic and clinical course factors].
    Sánchez de la Muela P; Rosell Costa D; Aguera Fernández L; de Castro Barbosa F; Isa Kroon WA; Robles García JE; Zudaire Bergera JJ; Berián Polo JM
    Actas Urol Esp; 1990; 14(5):341-4. PubMed ID: 2288251
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Assessment of clinical features in solitary minimum size (<1 cm) bladder cancer].
    Suzuki K; Nohda H; Funahashi M; Chiba K; Shinagawa T; Mizuno N; Fujikawa N; Murakami T; Ikeda I; Kono N
    Hinyokika Kiyo; 2012 Aug; 58(8):401-4. PubMed ID: 23052262
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Transurethral laser surgery of the treatment of bladder tumor].
    Okada K; Nakano A; Asaoka H; Amagai T
    Gan No Rinsho; 1985 May; 31(6 Suppl):685-9. PubMed ID: 3897619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Possibility of evaluating the degree of dissemination of malignant tumors of the bladder using ultrasonic tomography].
    Bal'ter SA; Matveev BP; Shipilov VI; Toktomushev AT; Mironova GT
    Vopr Onkol; 1986; 32(4):46-52. PubMed ID: 3518238
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The historical development of the staging of bladder tumors: personal reminiscences.
    Jewett HJ
    Urol Surv; 1977 Apr; 27(2):37-40. PubMed ID: 329533
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant radiotherapy in Ta, T1 and T2 bladder tumors after transurethral resection--a retrospective study.
    Rubben H; Lutzeyer W; Ebbinghaus KD; Dahm HH
    Prog Clin Biol Res; 1984; 162B():21-5. PubMed ID: 6438641
    [No Abstract]   [Full Text] [Related]  

  • 60. [Treatment of bladder tumors].
    Fürst F; Kottász S; Szollár G
    Acta Chir Acad Sci Hung; 1977; 18(3):263-5. PubMed ID: 605723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.